HUP9902034A2 - Szukcinimid- és maleimid citokin inhibitorvegyületek - Google Patents
Szukcinimid- és maleimid citokin inhibitorvegyületekInfo
- Publication number
- HUP9902034A2 HUP9902034A2 HU9902034A HUP9902034A HUP9902034A2 HU P9902034 A2 HUP9902034 A2 HU P9902034A2 HU 9902034 A HU9902034 A HU 9902034A HU P9902034 A HUP9902034 A HU P9902034A HU P9902034 A2 HUP9902034 A2 HU P9902034A2
- Authority
- HU
- Hungary
- Prior art keywords
- powder
- carbon
- tube powder
- substituents
- tube
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 title 2
- 102000004127 Cytokines Human genes 0.000 title 1
- 108090000695 Cytokines Proteins 0.000 title 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229960002317 succinimide Drugs 0.000 title 1
- -1 nitro- Chemical class 0.000 abstract 37
- 239000000843 powder Substances 0.000 abstract 28
- 229910052799 carbon Inorganic materials 0.000 abstract 10
- 125000001424 substituent group Chemical group 0.000 abstract 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 5
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- 239000000428 dust Substances 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 241000251468 Actinopterygii Species 0.000 abstract 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 abstract 1
- 239000005977 Ethylene Substances 0.000 abstract 1
- 125000003277 amino group Chemical class 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 150000001602 bicycloalkyls Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000002573 ethenylidene group Chemical group [*]=C=C([H])[H] 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A találmány tárgya az (I) általánős képletű vegyületek, ahől R1jelentése -CH2-csőpőrt, -CH2CO- csőpőrt vagy -CO-csőpőrt, R2 és R3jelentése együttesen (i) etiléncsőpőrt, amely egy vagy több 1-10szénatőmős alkilcsőpőrttal vagy fenilcsőpőrttal szűbsztitűált lehet,vagy szűbsztitűálatlan, (ii) viniléncsőpőrt, amely két szűbsztitűensttartalmaz, amely szűbsztitűensek egymástól függetlenek lehetnek, éslehetnek 1-10 szénatőmős alkilcsőpőrt és fenilcsőpőrt, vagy (iii)kétvegyértékű ciklőalkilcsőpőrt vagy biciklőalkilcsőpőrt, amely 5-10szénatőmőt tartalmaz, és amely szűbsztitűálatlan vagy szűbsztitűáltlehet, ahől a szűbsztitűensek egy vagy több szűbsztitűens, egymástólfüggetlenül lehetnek példáűl nitrő-, cianő-, triflűőr-metil-,karbetőxi-, karbőmetőxi-, karbőprőpőxi-, acetil-, karbamőilcsőpőrt,amely szűbsztitűált vagy szűbsztitűálatlan lehet, ahől a szűbsztitűenslehet 1-3 szénatőmős alkil-, acetőxi-, karbőxil-, hidrőxil-,aminőcsőpőrt, szűbsztitűált aminőcsőpőrt, 1-10 szénatőmősalkilcsőpőrt, 1-10 szénatőmős alkőxicsőpőrt, nőrbőrilcsőpőrt,fenilcsőpőrt vagy halőgénatőm, R4 jelentése (i) egyenes vagy elágazó szénláncú 4-8 szénatőmősalkilcsőpőrt, (ii) 5-10 szénatőmős ciklőalkilcsőpőrt, amely szűbsztitűálatlanvagy szűbsztitűált lehet, és egy vagy több szűbsztitűensttartalmazhat, amelyek egymástól függetlenül lehetnek nitrő-, cianő-,triflűőr-metil-, karbetőxi-, karbőmetőxi-, karbőprő- pőxi-, acetil-,karbamőil-, acetőxi-, karbőxil-, hidrőxil-, aminőcsőpőrt,szűbsztitűált aminőcsőpőrt, egyenes vagy elágazó szénláncú vagyciklűsős, 1-10 szénatőmőt tartalmazó alkilcsőpőrt, 1-10 szénatőmősalkőxicsőpőrt, fenilcsőpőrt vagy halőgénatőm, (iii) fenilcsőpőrt,amely egy vagy több szűbsztitűenst tartalmazhat, ahől aszűbsztitűensek egymástól függetlenül lehetnek nitrő-, cianő-,triflűőr-metil-, karbetőxi-, karbőmetőxi-, karbőprőpőxi-, acetil-,karbamőil-, acetőxi-, karbőxil-, hidrőxil-, aminőcsőpőrt,szűbsztitűált aminőcsőpőrt, 1-10 szénatőmős alkilcsőpőrt, 1-10szénatőmős alkőxicsőpőrt, 3-10 szénatőmős ciklőalkilcsőpőrt, 3-10szénatőmős ciklőalkőxicsőpőrt, fenilcsőpőrt vagy halőgénatőm, vagy(iv) 4-10 szénatőmős heterőciklűsős csőpőrt, amely egy vagy többheterőatőmőt tartalmazhat, ahől a heterőatőmők lehetnek nitrőgénatőm,őxigénatőm vagy kénatőm, mint példáűl piridincsőpőrt éspirrőlidincsőpőrt, amelyek szűbsztitűálatlanők vagy szűbsztitűáltaklehetnek, és egy vagy több szűbsztitűenst tartalmazhatnak, amelyszűbsztitűensek egymástól függetlenül lehetnek nitrő-, cianő-,triflűőr-metil-, karbetőxi-, karbőmetőxi-, karbőprőpőxi-, acetil-,karbamőil-, acetőxi-, karbőxil-, hidrőxil-, aminőcsőpőrt,szűbsztitűtált aminőcső- pőrt, 1-10 szénatőmős alkilcsőpőrt, 1-10szénatőmős alkőxicsőpőrt, fenilcsőpőrt vagy halőgénatőm, R5 jelentése-COX általán
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/539,879 US5658940A (en) | 1995-10-06 | 1995-10-06 | Succinimide and maleimide cytokine inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP9902034A2 true HUP9902034A2 (hu) | 1999-11-29 |
| HUP9902034A3 HUP9902034A3 (en) | 2001-01-29 |
Family
ID=24153040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9902034A HUP9902034A3 (en) | 1995-10-06 | 1996-10-04 | Succinimide and maleimide cytokine inhibitors |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5658940A (hu) |
| EP (1) | EP0862552B1 (hu) |
| JP (1) | JP3226546B2 (hu) |
| KR (1) | KR100345826B1 (hu) |
| AT (1) | ATE248145T1 (hu) |
| AU (1) | AU723915B2 (hu) |
| CA (1) | CA2233975C (hu) |
| CZ (1) | CZ105398A3 (hu) |
| DE (1) | DE69629716T2 (hu) |
| ES (1) | ES2206600T3 (hu) |
| FI (1) | FI119690B (hu) |
| HK (1) | HK1017885A1 (hu) |
| HU (1) | HUP9902034A3 (hu) |
| NZ (1) | NZ321001A (hu) |
| PL (1) | PL326063A1 (hu) |
| PT (1) | PT862552E (hu) |
| RU (1) | RU2176242C2 (hu) |
| SK (1) | SK44698A3 (hu) |
| WO (1) | WO1997012859A1 (hu) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
| US5801195A (en) | 1994-12-30 | 1998-09-01 | Celgene Corporation | Immunotherapeutic aryl amides |
| US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| EP1361210B1 (en) * | 1996-08-12 | 2008-12-24 | Celgene Corporation | Novel immunotherapeutic agents and their use in the reduction of cytokine levels |
| US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| AU2006200033B8 (en) * | 1998-10-30 | 2008-09-11 | Celgene Corporation | Substituted phenethylsulfones and methods of reducing TNF-alpha levels |
| US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
| WO2001005779A2 (en) * | 1999-07-15 | 2001-01-25 | Cytoclonal Pharmaceutics, Inc. | Method of designing tubulin polymerization stabilizers |
| US7122666B2 (en) * | 1999-07-21 | 2006-10-17 | Sankyo Company, Limited | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses |
| US6667316B1 (en) | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
| US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| US6699899B1 (en) * | 1999-12-21 | 2004-03-02 | Celgene Corporation | Substituted acylhydroxamic acids and method of reducing TNFα levels |
| US6326388B1 (en) | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
| US20010051348A1 (en) * | 2000-01-28 | 2001-12-13 | Lee Chee Wee | Novel ligands and methods for preparing same |
| US8030343B2 (en) * | 2000-06-08 | 2011-10-04 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
| US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| US7491634B2 (en) * | 2006-04-28 | 2009-02-17 | Asm International N.V. | Methods for forming roughened surfaces and applications thereof |
| GB0125658D0 (en) * | 2001-10-25 | 2001-12-19 | Ssl Int Plc | Medicaments |
| US7893101B2 (en) * | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| US7276529B2 (en) * | 2002-03-20 | 2007-10-02 | Celgene Corporation | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
| US7208516B2 (en) * | 2002-03-20 | 2007-04-24 | Celgene Corporation | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
| MXPA04009997A (es) * | 2002-04-12 | 2004-12-13 | Celgene Corp | Modulacion de la diferenciacion de celulas madre y progenitoras, ensayos y usos de las mismas. |
| WO2003086373A1 (en) * | 2002-04-12 | 2003-10-23 | Celgene Corporation | Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds |
| US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| EP2258363A1 (en) * | 2002-05-17 | 2010-12-08 | Celgene Corporation | Compositions for treatment of cancers |
| US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
| BR0313330A (pt) * | 2002-08-10 | 2005-06-14 | Altana Pharma Ag | Piperidina-ftalazonas substituìdas com pirrolidinadiona como inibidores de pde4 |
| US6774758B2 (en) * | 2002-09-11 | 2004-08-10 | Kalyan P. Gokhale | Low harmonic rectifier circuit |
| EP1551385A4 (en) * | 2002-10-15 | 2008-10-22 | Celgene Corp | SELECTIVE CYTOKINE INHIBITOR DRUGS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES |
| US20040087558A1 (en) | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| US7776907B2 (en) * | 2002-10-31 | 2010-08-17 | Celgene Corporation | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
| US7354948B2 (en) | 2002-11-06 | 2008-04-08 | Celgene Corporation | Methods for treatment of chronic uveitis using cyclopropyl-n-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
| CA2505003A1 (en) * | 2002-11-06 | 2004-05-27 | Celgene Corporation | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
| BR0316256A (pt) * | 2002-11-18 | 2005-10-04 | Celgene Corp | Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto |
| AU2003294311B8 (en) * | 2002-11-18 | 2008-06-05 | Celgene Corporation | Method of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
| US20050187278A1 (en) * | 2003-08-28 | 2005-08-25 | Pharmacia Corporation | Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors |
| US20050142104A1 (en) * | 2003-11-06 | 2005-06-30 | Zeldis Jerome B. | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders |
| NZ547689A (en) | 2003-11-19 | 2009-05-31 | Signal Pharm Llc | Indazole compounds and methods of use thereof as protein kinase inhibitors |
| US20080213213A1 (en) * | 2004-04-14 | 2008-09-04 | Zeldis Jerome B | Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione |
| AU2005234783A1 (en) * | 2004-04-23 | 2005-11-03 | Celgene Corporation | Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension |
| US7244759B2 (en) * | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
| US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| CA2585423A1 (en) * | 2004-10-28 | 2006-05-11 | Celgene Corporation | Methods and compositions using pde4 modulators for treatment and management of central nervous system injury |
| US20080138295A1 (en) * | 2005-09-12 | 2008-06-12 | Celgene Coporation | Bechet's disease using cyclopropyl-N-carboxamide |
| US8853257B2 (en) | 2005-11-21 | 2014-10-07 | Mordechai Sharir | Succinimide derivatives as ocular hypotensive agents |
| EP1951229B1 (en) * | 2005-11-21 | 2013-07-10 | Mordechai Sharir | Succinimide derivatives as ocular hypotensive agents |
| US20070155791A1 (en) * | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
| UA98494C2 (uk) * | 2007-06-29 | 2012-05-25 | Гіліад Сайєнсіз, Інк. | Противірусні сполуки |
| JP2011515469A (ja) * | 2008-03-24 | 2011-05-19 | セルジーン コーポレイション | シクロプロピル−ｎ−｛２−［（１ｓ）−１−（３−エトキシ−４−メトキシフェニル）−２−（メチルスルホニル）エチル］−３−オキソイソインドリン−４−イル｝カルボキサミドを使用した乾癬又は乾癬性関節炎の治療 |
| US8092822B2 (en) * | 2008-09-29 | 2012-01-10 | Abbott Cardiovascular Systems Inc. | Coatings including dexamethasone derivatives and analogs and olimus drugs |
| UA103791C2 (uk) | 2009-02-10 | 2013-11-25 | Селджин Корпорейшн | Композиція, що включає модулятор pde4, і спосіб її застосування для лікування, профілактики або супроводу туберкульозу |
| JP5937060B2 (ja) | 2010-04-07 | 2016-06-22 | セルジーン コーポレイション | 呼吸器ウイルス感染症の治療方法 |
| JP2013531499A (ja) | 2010-06-15 | 2013-08-08 | セルジーン コーポレイション | 乾癬の治療のためのバイオマーカー |
| CN103788076B (zh) * | 2014-01-22 | 2015-06-03 | 山西大学 | 一种检测半胱氨酸的试剂和方法 |
| EP3142663A1 (en) | 2014-05-16 | 2017-03-22 | Celgene Corporation | Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators |
| JP6687550B2 (ja) | 2014-06-23 | 2020-04-22 | セルジーン コーポレイション | 肝疾患又は肝機能異常を治療するためのアプレミラスト |
| US10682336B2 (en) | 2015-10-21 | 2020-06-16 | Amgen Inc. | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) |
| CN109195943B (zh) * | 2016-06-03 | 2021-11-23 | 捷恩智株式会社 | 聚合性极性化合物、液晶组合物及液晶显示元件 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2852526A (en) * | 1955-05-03 | 1958-09-16 | Schering Corp | Substituted pyrrolidines |
| GB1539817A (en) * | 1976-10-22 | 1979-02-07 | Ucb Sa | N-substituted lactams |
| FR2418790A1 (fr) * | 1978-03-02 | 1979-09-28 | Philagro Sa | Nouveaux derives de pyrrolidinone-2 et compositions herbicides les contenant |
| US4394369A (en) * | 1982-05-24 | 1983-07-19 | Fmc Corporation | Hydrogen peroxide process |
| US4996199A (en) * | 1988-04-08 | 1991-02-26 | Whitby Research, Inc. | Penetration enhancers for transdermal delivery of systemic agents |
| GB9013142D0 (en) * | 1990-06-13 | 1990-08-01 | Ciba Geigy Ag | Chemical compounds useful as metal deactivators |
| AU1531492A (en) * | 1991-02-14 | 1992-09-15 | Rockefeller University, The | Method for controlling abnormal concentration tnf alpha in human tissues |
| PT100441A (pt) * | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso |
| US5204366A (en) * | 1991-06-10 | 1993-04-20 | American Cyanamid Company | 2,5-dioxo-3-pyrroline-1-acetanilide fungicidal agents, compositions and method for use thereof |
| US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| AU696817B2 (en) * | 1994-12-30 | 1998-09-17 | Celgene Corporation | Immunotherapeutic imides/amides and their use for reducing levels of TNF alpha |
-
1995
- 1995-10-06 US US08/539,879 patent/US5658940A/en not_active Expired - Lifetime
-
1996
- 1996-10-04 AU AU73873/96A patent/AU723915B2/en not_active Ceased
- 1996-10-04 EP EP96936155A patent/EP0862552B1/en not_active Expired - Lifetime
- 1996-10-04 ES ES96936155T patent/ES2206600T3/es not_active Expired - Lifetime
- 1996-10-04 KR KR1019980702531A patent/KR100345826B1/ko not_active IP Right Cessation
- 1996-10-04 SK SK446-98A patent/SK44698A3/sk unknown
- 1996-10-04 JP JP51442097A patent/JP3226546B2/ja not_active Expired - Fee Related
- 1996-10-04 CZ CZ981053A patent/CZ105398A3/cs unknown
- 1996-10-04 WO PCT/US1996/015864 patent/WO1997012859A1/en active IP Right Grant
- 1996-10-04 AT AT96936155T patent/ATE248145T1/de not_active IP Right Cessation
- 1996-10-04 RU RU98108602/04A patent/RU2176242C2/ru not_active IP Right Cessation
- 1996-10-04 DE DE69629716T patent/DE69629716T2/de not_active Expired - Lifetime
- 1996-10-04 PL PL96326063A patent/PL326063A1/xx unknown
- 1996-10-04 PT PT96936155T patent/PT862552E/pt unknown
- 1996-10-04 CA CA002233975A patent/CA2233975C/en not_active Expired - Fee Related
- 1996-10-04 HU HU9902034A patent/HUP9902034A3/hu unknown
- 1996-10-04 NZ NZ321001A patent/NZ321001A/en not_active IP Right Cessation
-
1998
- 1998-04-03 FI FI980776A patent/FI119690B/fi active IP Right Grant
-
1999
- 1999-03-08 HK HK99100926A patent/HK1017885A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FI119690B (fi) | 2009-02-13 |
| AU723915B2 (en) | 2000-09-07 |
| CA2233975C (en) | 2005-12-06 |
| FI980776A0 (fi) | 1998-04-03 |
| PT862552E (pt) | 2003-12-31 |
| EP0862552A1 (en) | 1998-09-09 |
| PL326063A1 (en) | 1998-08-17 |
| ATE248145T1 (de) | 2003-09-15 |
| RU2176242C2 (ru) | 2001-11-27 |
| US5658940A (en) | 1997-08-19 |
| AU7387396A (en) | 1997-04-28 |
| JP3226546B2 (ja) | 2001-11-05 |
| SK44698A3 (en) | 1998-09-09 |
| HUP9902034A3 (en) | 2001-01-29 |
| CA2233975A1 (en) | 1997-04-10 |
| KR100345826B1 (ko) | 2002-11-18 |
| CZ105398A3 (cs) | 1998-07-15 |
| FI980776L (fi) | 1998-06-05 |
| EP0862552B1 (en) | 2003-08-27 |
| DE69629716D1 (en) | 2003-10-02 |
| NZ321001A (en) | 2001-03-30 |
| ES2206600T3 (es) | 2004-05-16 |
| JPH11513387A (ja) | 1999-11-16 |
| DE69629716T2 (de) | 2004-07-08 |
| WO1997012859A1 (en) | 1997-04-10 |
| HK1017885A1 (en) | 1999-12-03 |
| KR19990064052A (ko) | 1999-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP9902034A2 (hu) | Szukcinimid- és maleimid citokin inhibitorvegyületek | |
| CA2079143A1 (en) | Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace | |
| CA2078758A1 (en) | 2-substituted indane-2-mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace | |
| CA2078759A1 (en) | Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace | |
| HUP9902341A2 (hu) | Herpeszvírus elleni hatású fenil-tiazol-származékok, előállításuk és alkalmazásuk, a vegyületeket tartalmazó gyógyszerkészítmények | |
| HUP9800295A2 (hu) | Szubsztituált heterociklusos vegyületek, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények, intermedierjeik | |
| DK0915866T3 (da) | Forbedret fremgangsmåde til syntese af beskyttende estere af (S)-3,4-dihydroxysmørsyre | |
| MX9203165A (es) | Derivados de succinimida y composicion farmaceutica que los contiene . | |
| BR0315405A (pt) | Compostos inibidores da integrase tricìclica pré-organizados | |
| CA2053340A1 (en) | Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace | |
| DK135991A (da) | 1h-imidazooe4,5-caaquinolin-5-oxyforbindelse | |
| HUP9601176A2 (hu) | Adhéziós receptor antagonista amidinszármazékok, az ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra | |
| HK1039727B (zh) | 海鞘素-743的合成類似物 | |
| CA2111319A1 (fr) | Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii | |
| HUP9801838A2 (hu) | Specifikus ingerlő aminosav antagonista indolszármazékok | |
| AU2736088A (en) | Pharmaceutical compositions comprising benzylidene- and cinnamylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells, certain such novel compounds and their preparation | |
| RU94011232A (ru) | Соли щелочноземельных металлов, соли переходных металлов и комплексы переходных металлов кетокарбоновых кислот в качестве ингибиторов коррозии | |
| AU9426098A (en) | Azetidinone derivatives for the treatment of hcmv infections | |
| DK0542609T3 (da) | 3-sulfonylamino-2-(1H)-quinolinon og 7-azaderivater heraf som excitatoriske aminosyre-anta-gonister | |
| ATE67193T1 (de) | 6-phenyl-pyridazin-verbindungen. | |
| CA2280730A1 (en) | Substituted (1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9h-purin-8-yl)phenyl derivatives, their preparation and their use in the treatment of inflammatory conditions and immune disorders | |
| TR200001239T2 (tr) | Tiyazolidinediyon türevlerini hazırlama prosesi. | |
| KR950704278A (ko) | 세포내 포스포리파제 a₂저해 활성을 갖는 옥사졸리논 유도체(oxazolinone derivative having intracellular phospholipase a₂inhibitor activity) | |
| CA2209422A1 (en) | 4-amino-3-acylnaphthyridine derivatives | |
| HUP9702393A2 (hu) | bisz(2-Halogén-etil)-amino-fenil szubsztituált distamycinszármazékok, tumorellenes és vírusellenes hatóanyagok |